Evidence map›Paper›PMID 27671488›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2017

Assessment of health-related quality of life, mental health status and psychological distress based on the type of pharmacotherapy used among patients with depression.

Drishti Shah, Varun Vaidya, Amit Patel, Mary Borovicka, Monica-Holiday Goodman

Abstract read
PubMed Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Drishti ShahDepartment of Pharmaceutical Systems and Policy,School of Pharmacy, West Virginia University, Morgantown, WV, 26506, USA. drshah@mix.wvu.edu.
Varun VaidyaDivision of Health Outcomes and Socio-economic Sciences, Department of Pharmacy Practice, College of Pharmacy and Pharmaceutical Sciences, The University of Toledo, Toledo, OH, USA.
Amit PatelMedical Marketing Economics, LLC, 1200 Jefferson Ave., Suite 200, Oxford, MS, 38655, USA.
Mary BorovickaDepartment of Pharmacy Practice, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH, USA.
Monica-Holiday GoodmanDivision of Health Outcomes and Socio-economic Sciences, Department of Pharmacy Practice, College of Pharmacy and Pharmaceutical Sciences, The University of Toledo, Toledo, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeEffectiveness of antidepressants is generally comparable between and within classes. However, real-world studies on antidepressant treatment and its consequences on the overall quality of life and mental health of individuals are limited. The purpose of this study was to examine the association of specific class of antidepressants with the health-related quality of life, psychological distress and self-reported mental health of individuals suffering from depression who are on monotherapy.

methodsThis retrospective, longitudinal study included individuals with depression who were on antidepressant monotherapy, using data from 2008 to 2011 Medical Expenditure Panel Survey (MEPS). Changes in health-related quality of life, self-reported mental health and psychological distress over a year's time were observed. A multinomial logistic regression model was built to examine the association between the class of antidepressant medications and the dependent variables.

resultsA total of 688 adults met the study inclusion criteria. No significant difference was observed in the change in Physical Component Summary (PCS), self-reported mental health and psychological distress based on the class of antidepressants. However, individuals on serotonin-norepinephrine reuptake inhibitors (SNRIs) (OR 0.337, 95 % CI 0.155-0.730) were significantly less likely to show improvement on Mental Component Summary (MCS) scores as compared to those on selective serotonin reuptake inhibitors (SSRIs).

conclusionsThe study findings suggest that practitioners should be aware of the differences in the health-related quality of life of those taking SSRIs versus other classes of antidepressants. Further research needs to be done to determine the reason for SSRIs to show greater improvement on mental health as compared to SNRIs.

Indexed as

Quality of LifeAdolescentAdultAntidepressive AgentsDepressive DisorderFemaleHealth SurveysHumansLogistic ModelsLongitudinal StudiesMaleMiddle AgedRetrospective StudiesSelective Serotonin Reuptake InhibitorsUnited StatesYoung AdultAntidepressive AgentsSelective Serotonin Reuptake InhibitorsAntidepressantsDepressionHealth-related quality of lifeMental healthPsychological distress

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.